Login to Your Account

Cladribine Falters, Biotech MS Candidates Move Up

By Catherine Shaffer

Thursday, March 3, 2011
A complete response letter caps the latest chapter in the troubled tale of EMD Serono Inc.'s cladribine tablets for relapsing and remitting multiple sclerosis (MS). The German company, an affiliate of Merck KGaA, has struggled to get the drug through the U.S. and European regulatory gauntlet, suffering setbacks nearly every step of the way.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription